Skip to main content

Table 1 Summary of characteristics of arenavirus-derived HLA-DRB1*0101-restricted CD4+ T cell epitopes.

From: Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverage

Epitopea Sequence DRB1*0101 binding affinity
(IC50 nM)b 		ELISPOT
(net SFC/106 CD4+)c 		ICS
(%IFN-γ+ CD4+)d
GTOV GPC131-145 KGSPEFDWILGWTIK 1.7 208 0.22
GTOV L181-195 DQEYHRLIHSLSKTS 0.34 390 0.05
GTOV L391-405 RVLDILVARRLLLKK 0.19 330 0.11
GTOV L1826-1840 IQLVFSSMINPLVIT 0.23 163 0.04
GTOV NP166-180 KLNNQFGSMPALTIA 0.12 122 0.05
GTOV NP191-205 NNVVQALTSLGLLYT 0.29 97 0.05
GTOV NP236-250 ISGYNFSLSAAVKAG 0.12 126 0.03
GTOV NP541-555 IPIQLLPNTLVFQAK 0.25 142 0.11
JUNV GPC46-60 FFVFLALAGRSCTEE 0.23 684 0.06
JUNV L381-395 VGQMLMLVNDRLLDI 0.21 323 0.06
JUNV L391-405 RLLDILEAIKLIRKK 0.48 333 0.08
JUNV L411-425 KWVQMCSRTLKNSHQ 1.1 571 0.05
JUNV L1491-1505 MFIRNCARKVFNDIK 2.0 425 0.11
JUNV L1711-1725 NKNFFWAVKPKAVRQ 0.06 538 0.16
LASV GPC236-250 PSPIGYLGLLSQRTR 0.14 497 0.07
LASV GPC241-255 YLGLLSQRTRDIYIS 0.29 469 0.05
LASV GPC476-490 SCGLYKQPGVPVRWK 1.5 273 0.04
LCMV GPC421-435 LRKDYIKRQGSTPLA 4.8 268 0.16
LCMV L256-270 RNFQKVNPEGLIKEF 5.6 217 0.07
LCMV L946-960 HLRKVILSEISFHLV 2.1 533 0.07
LCMV NP6-20 EVKSFQWTQALRREL 49 436 0.07
LCMV NP521-535 MDCIIFESASKARLP 4.4 463 0.12
MACV GPC96-110 NSFYYMKGGVNTFLI 0.21 365 0.08
MACV GPC251-265 SKTHLNFERSLKAFF 1.7 427 0.12
MACV GPC446-460 ASLFLHLVGIPTHRH 0.13 329 0.08
MACV L391-405 DRVLDILEAVKLIRK 0.48 423 0.22
MACV L636-650 RYFLMAFANQIHHID 0.24 269 0.06
MACV L866-880 DYLILKNLTGLVSAG 0.21 322 0.13
MACV L1491-1505 TSFIRNCARKVFNDI 0.11 400 0.07
MACV L1711-1725 NNQNFFWAVKPKVVR 1.7 518 0.09
MACV NP191-205 NSVVQALTSLGLLYT 0.78 176 0.06
MACV Z21-35 PSAEFRRTAPPSLYG 2.0 313 0.16
SABV GPC26-40 VSLIAALKGMINLWK 0.47 264 0.04
SABV GPC436-450 FTTTLFLHLVGFPTH 0.92 1213 0.08
SABV GPC441-455 FLHLVGFPTHRHIRG 0.09 823 0.05
WWAV GPC46-60 FIVFLLLAGRSCSYK 1.2 701 0.10
WWAV GPC386-400 FRNQWLLESDHLISE 1.6 517 0.39
  1. a Peptide position within the GPC, L, NP, or Z protein of prototypic strains of GTOV, JUNV, LASV, LCMV, MACV, SABV, and WWAV.
  2. b Each epitope was tested for binding to HLA-DRB1*0101.
  3. c Peptide tested at 10 μg/ml in IFN-γ ELISPOT assays. Criteria for positivity are net SFC/106 cells ≥ 20, SI ≥ 1.4, and p-value ≤ 0.05 in two or more independent assays. Average IFN-γ responses are shown from two independent experiments.
  4. d Peptide tested at 3 μg/ml in IFN-γ ICS assays. The epitope-specific responses were calculated by subtracting the total number of cells that scored positive for IFN-γ+ production in the absence of peptide. Criterion for positivity is SI ≥ 2.0 in two or more independent assays. Average IFN-γ responses are shown from two independent experiments.
Back to article page

Immunome Research

ISSN: 1745-7580